Enclomiphene and testosterone gel can both raise serum testosterone in selected men with secondary hypogonadism, but they do so through different endocrine routes. Enclomiphene increased LH and FSH and maintained sperm concentration in short-term trials; gel suppressed those signals and reduced spermatogenesis. Similar blood testosterone does not establish similar symptom relief, hypertrophy, fertility outcomes or long-term safety.
From Enclomiphene vs Testosterone · Editorial update 2026-10-16
Mechanisms explain possibilities. Outcomes, populations and study limitations determine what the evidence supports.
What it is & what research shows
Study example available
Testosterone is the principal endogenous androgen. Testosterone cypionate is an injectable ester that releases testosterone after intramuscular administration. The cited label covers replacement therapy in males with symptoms or conditions associated with deficiency or absence of endogenous testosterone, including primary and hypogonadotropic hypogonadism.[1.1]
One selected study: Randomized trial comparing weekly testosterone enanthate or placebo, each with or without standardized resistance training. Forty-three normal men received 600 mg testosterone enanthate or placebo weekly for 10 weeks; exercise groups lifted three times weekly. In this 10-week randomized study of 43 men, the testosterone groups received injections of 600 mg testosterone enanthate once weekly; comparator groups received placebo injections. Exercise groups also performed standardized weight-lifting three times weekly. This describes the study intervention, not a recommended regimen. Testosterone plus exercise increased fat-free mass by 6.1 kg; bench-press strength rose 22 kg and squat capacity 38 kg. Testosterone without exercise also outperformed placebo for measured muscle size and strength. Mood and behavior were unchanged. This was a small, 10-week study in normal men using a supraphysiologic regimen. The abstract reports mood and behavior but no longer-term safety assessment or author-stated limitations.[2.1]
Studied methods, not dosing advice. Selected evidence, not a complete literature review or formal quality appraisal. Read the study summary
Source scope is listed with each reference. Prepared by PED Evidence with AI assistance. Independent clinician review has not been completed. Review standards
Evidence summarized on PED Evidence
73 completed summaries
46 human-study reports
21 randomized-trial candidates
13 safety-topic reports
These counts describe completed summaries on this site, not the size of the full literature. Publications can share participants; design labels are discovery metadata, not appraisals.
High-grade prostate cancer occurred in 5 of 2,596 testosterone-treated men and 3 of 2,602 placebo-treated men. The difference was not statistically significant; PSA rose more with testosterone.
Limitations & adverse findings
This is a TRAVERSE analysis, sharing its registration with the cardiovascular report.
What might this mean? · interpretation
Low event counts in screened men support a limited conclusion, not proof of no long-term prostate risk.
What might this mean, and what would change the interpretation?
Participants at high prostate-cancer risk were excluded. Few events and limited follow-up constrain precision.
What would clarify this: Longer follow-up and evidence in populations excluded from this trial.
Findings reviewed · abstract
Checked Sep 15, 2026 against the linked abstract. This reading note is not a formal risk-of-bias appraisal.
1.62% gel targeting 350–750 ng/dL; mean treatment 21.7 months, follow-up 33 months.
Demonstrated findings
The primary cardiovascular event occurred in 7.0% with testosterone and 7.3% with placebo. The trial met its prespecified noninferiority criterion.
Limitations & adverse findings
Atrial fibrillation, acute kidney injury and pulmonary embolism occurred more often in the testosterone group.
What might this mean? · interpretation
This supports a bounded conclusion about major cardiovascular events in the studied replacement setting.
What might this mean, and what would change the interpretation?
5,246 men aged 45–80 with low testosterone and existing or increased cardiovascular risk. Results do not establish safety at higher exposures or across all formulations.
What would clarify this: Longer follow-up and studies of different exposures and delivery methods.
Findings reviewed · abstract
Checked Sep 15, 2026 against the linked abstract. This reading note is not a formal risk-of-bias appraisal.
Daily gel versus placebo for 1 year; men aged 65 or older.
Demonstrated findings
In the 493-person memory-impaired subgroup, testosterone did not significantly improve verbal memory, visual memory, executive function or spatial ability versus placebo.
Limitations & adverse findings
This report shares the Testosterone Trials registration with other reports; it is not an independent trial population.
What might this mean? · interpretation
Improved hormone levels did not translate into cognitive gains on these tests.
What might this mean, and what would change the interpretation?
Older men with low testosterone and age-associated memory impairment; this does not resolve every cognitive question in younger adults.
What would clarify this: Replication in different populations using prespecified cognitive and daily-function outcomes.
Findings reviewed · abstract
Checked Sep 15, 2026 against the linked abstract. This reading note is not a formal risk-of-bias appraisal.
400 men across two cohorts; 16 weeks; gel and controlled suppression.
Demonstrated findings
Under experimental hormone suppression, androgen deficiency accounted for loss of lean mass, muscle size and strength. Estrogen deficiency mainly accounted for increased body fat; both contributed to reduced sexual function.
What might this mean? · interpretation
Reducing estrogen is not automatically aligned with improving every body-composition or sexual outcome.
What might this mean, and what would change the interpretation?
Healthy men received hormone suppression and graded gel doses, with or without anastrozole. This does not define an optimal estradiol target during routine treatment.
What would clarify this: Trials testing specific clinical questions about estradiol management.
Findings reviewed · abstract
Checked Sep 15, 2026 against the linked abstract. This reading note is not a formal risk-of-bias appraisal.
20 weeks; weekly enanthate with a GnRH agonist. These are experimental regimens.
Demonstrated findings
Across graded testosterone exposures, fat-free mass, muscle size and strength increased with dose. Mood and sexual function did not significantly change at any dose.
Selected groups from this experiment
Studied dose
Mean trough total T
Fat-free mass change
125 mg/week
542 ng/dL
+3.4 kg
300 mg/week
1,345 ng/dL
+5.2 kg
600 mg/week
2,370 ng/dL
+7.9 kg
Group averages at the studied regimens, not a dosing recommendation or prediction of personal gains.
Limitations & adverse findings
Hemoglobin increased and HDL cholesterol decreased with higher concentrations. Fat-free mass includes more than muscle.
What might this mean? · interpretation
Different outcomes can respond differently to increasing hormone exposure.
What might this mean, and what would change the interpretation?
61 healthy men aged 18–35; endogenous production was suppressed. Short-term group averages cannot predict an individual response.
What would clarify this: Longer trials measuring function and adverse outcomes across comparable exposures.
Findings reviewed · abstract
Checked Sep 15, 2026 against the linked abstract. This reading note is not a formal risk-of-bias appraisal.
More about Testosterone: identity, safety & reference details
Small moleculeEndocrine & hormones
Primary research area
Endocrine · muscle & performance
Regulatory status
Prescription medicine
Evidence level
Human, indication-specific
Primary mechanism
Androgen-receptor agonist; converts partly to estradiol and DHT
Reference profile available · Coverage varies by section
Also known as Testosterone cypionate · Testosterone enanthate · Testosterone propionate · Testosterone undecanoate · Testosterone phenylpropionate · Testosterone isocaproate · Testosterone suspension · Sustanon · mixed testosterone esters · Sustanon / mixed testosterone esters · Sustanon 250 · Nebido · Aveed · Testosterone base / no ester
What has been observed?
Selected source-linked reading notes, not the complete literature or a pooled conclusion.
Human · Abstract reviewed
What does the prostate analysis leave unresolved?
Topical gel versus placebo; 5,204 men analyzed.
High-grade prostate cancer occurred in 5 of 2,596 testosterone-treated men and 3 of 2,602 placebo-treated men. The difference was not statistically significant; PSA rose more with testosterone.
Limits & adverse findings: Participants at high prostate-cancer risk were excluded. Few events and limited follow-up constrain precision. This is a TRAVERSE analysis, sharing its registration with the cardiovascular report.
What did TRAVERSE establish about cardiovascular events?
1.62% gel targeting 350–750 ng/dL; mean treatment 21.7 months, follow-up 33 months.
The primary cardiovascular event occurred in 7.0% with testosterone and 7.3% with placebo. The trial met its prespecified noninferiority criterion.
Limits & adverse findings: 5,246 men aged 45–80 with low testosterone and existing or increased cardiovascular risk. Results do not establish safety at higher exposures or across all formulations. Atrial fibrillation, acute kidney injury and pulmonary embolism occurred more often in the testosterone group.
The cited label covers replacement therapy in males with symptoms or conditions associated with deficiency or absence of endogenous testosterone, including primary and hypogonadotropic hypogonadism. [1]
Known half-life
About 8 days after intramuscular testosterone cypionate administration. This value is specific to the cypionate ester and route, not every testosterone preparation. [1]
Half-life describes how quickly the measured drug concentration falls by half. It does not set a dosing interval.
Evidence & important limits
Replacement labeling does not establish an optimal muscle-gain exposure. The label says the product has not been shown safe and effective for athletic enhancement and describes risks including suppression of sperm production, polycythemia, edema and possible lipid changes. [1]
Safety & evidence boundaries
Source-specific information, not a personal safety clearance or monitoring plan.
Replacement labeling does not establish an optimal muscle-gain exposure. The label says the product has not been shown safe and effective for athletic enhancement and describes risks including suppression of sperm production, polycythemia, edema and possible lipid changes.
Interactions, rare harms, long-term effects and reversibility require separate evidence. Do not infer they are absent when the sources here do not address them.
Combination evidence stays attached to the studied combination. It is not automatically assigned to each ingredient.
Understand the evidence types
Read the model and design first, then the population, outcome and limitations. These categories describe evidence, not a best-compound ranking.
Randomized human trials
Compare assigned interventions. Randomization does not by itself establish low bias or relevance to every population.
Controlled human studies
Use a comparison group; allocation and confounding still matter.
Prospective human research
Follows participants forward. It may be observational or interventional, so this is not a separate quality grade.
Observational human research
Describes associations. Confounding can explain differences.
Case reports and series
Useful for unusual events and safety signals, not reliable rates or effect sizes.
Animal research
Can test biology and function in a living model. Human exposure, benefit and safety remain separate questions.
Cell and tissue research
Tests responses in a preparation, including human-derived cells. It is not a human participant trial.
Mechanistic and computational evidence
Helps explain or predict a pathway; predictions need experimental and clinical testing.
Anecdotal reports
Self-reported experiences can generate questions. Product identity, selection bias and other interventions may be uncontrolled.
Systematic reviews synthesize studies and depend on their quality. Preprint status and abstract versus full-paper reading are separate labels. Citation popularity measures attention, not reliability. A study summary is not a formal quality appraisal.
Reference facts checked 2026-09-16. Source scope is listed above; this is not a formal quality appraisal. See each label for full prescribing information.
Candidate categories use titles and any reviewed intervention metadata. Treatment candidates can include reviews or protocols; this filter does not certify a treatment experiment.
Study model describes the source. Confidence depends on methods, replication, population and outcome.
Loading compound research…
Testosterone study summaries
Human-first reading order. Intervention candidates are distinguished from background mentions in the library.